2 University Plaza
Hackensack, NJ 07601
201 696 9345
Full Time Employees: 193
|Mr. Dror Bashan||Pres, CEO & Director||490.1k||N/A||1967|
|Mr. Eyal Rubin M.B.A.||Sr. VP, CFO, Treasurer & Corp. Sec.||430.56k||N/A||1976|
|Mr. Yaron Naos||Sr. VP of Operations||N/A||N/A||1964|
|Ms. Yael Fellous||VP of HR||N/A||N/A||N/A|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Protalix BioTherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.